Effectiveness and Safety of Reduced and Standard Daily Doses of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: A Cohort Study Using National Database Representing the Japanese Population

References

• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. Circulation. 2019;140:e125–e151. doi:10.1161/CIR.0000000000000665
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Ono K, Iwasaki Y, Shimizu W, et al. JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. Available from: https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf. Accessed January 2, 2022.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi:10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi:10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Tanigawa T, Kaneko M, Hashizume K, et al. Model-based dose selection for Phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 2013;28(1):59–70. doi:10.2133/dmpk.dmpk-12-rg-034
   PubMed Web of Science ®Google Scholar
• Chao TF, Hong KS, Lee BC, et al. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF program. J Chin Med Assoc. 2021;84:485–490. doi:10.1097/JCMA.0000000000000516
   Web of Science ®Google Scholar
• Shen NN, Zhang C, Hang Y, et al. Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: an epidemiological meta-analysis. Front Pharmacol. 2021;12:581293. doi:10.3389/fphar.2021.581293
   Web of Science ®Google Scholar
• Stoll S, Macha K, Marsch A, et al. Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation. J Neurol. 2020;267:2007–2012. doi:10.1007/s00415-020-09795-3
   Web of Science ®Google Scholar
• Ueda A, Toki S, Kitayama C, Akazawa M. Reduction in the doses of direct oral anticoagulants and risk of ischemic stroke events: a hospital survey. Biol Pharm Bull. 2020;43:1135–1140. doi:10.1248/bpb.b19-00798
   Web of Science ®Google Scholar
• Eschler CM, Woitok BK, Func GC, et al. Oral anticoagulation in patients in the emergency department: high rates of off-label doses, no difference in bleeding rates. Am J Med. 2020;133:599–604. doi:10.1016/j.amjmed.2019.09.026
   Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164. doi:10.1161/CIRCULATIONAHA.114.012061
   PubMed Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790. doi:10.1016/j.jacc.2017.03.600
   PubMed Web of Science ®Google Scholar
• Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US medicare part D data. Am J Cardiovasc Drugs. 2017;17(1):37–47. doi:10.1007/s40256-016-0189-9
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Fay M, Amara W. The importance of appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation. TH Open. 2021;5(3):e353–e362. doi:10.1055/s-0041-1731777
   Google Scholar
• Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. Thromb Haemost. 2016;115(5):939–949. doi:10.1160/TH15-10-0840
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. doi:10.1136/bmj.j510
   PubMed Web of Science ®Google Scholar
• Helmert S, Marten S, Mizera H, et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. J Thromb Thrombolysis. 2017;44(2):169–178. doi:10.1007/s11239-017-1519-8
   Web of Science ®Google Scholar
• Godino C, Bodega F, Melillo F, et al. Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation. J Cardiovasc Med. 2020;21(10):751–758. doi:10.2459/JCM.0000000000001043
   Google Scholar
• Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019;132:847–855. doi:10.1016/j.amjmed.2019.01.025
   Web of Science ®Google Scholar
• Chan YH, Chao TF, Chen SW, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. Heart Rhythm. 2020;17:2102–2110. doi:10.1016/j.hrthm.2020.07.022.Yu
   Web of Science ®Google Scholar
• Lee KN, Choi JI, Boo KY, et al. Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep. 2020;10:1801. doi:10.1038/s41598-020-58665-5
   Web of Science ®Google Scholar
• Cheng WH, Chao TF, Lin YJ, et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. Stroke. 2019;50:2574–2577. doi:10.1161/STROKEAHA.119.025623
   Web of Science ®Google Scholar
• Ikeda T, Ogawa S, Kitazono T, et al. Outcomes associated with under‑dosing of rivaroxaban for management of non‑valvular atrial fibrillation in real‑world Japanese clinical settings. J Thromb Thrombolysis. 2019;48:653–660. doi:10.1007/s11239-019-01934-6
   Web of Science ®Google Scholar
• Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of recurrent ischemic stroke with unintended low-dose oral anticoagulant therapy and optimal timing of review. J Stroke Cerebrovasc Dis. 2018;27:1546–1551. doi:10.1016/j.jstrokecerebrovasdis.2018.01.002
   Web of Science ®Google Scholar
• Lee SR, Choi EK, Park SH, et al. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):415–423. doi:10.1093/ehjcvp/pvab004
   Web of Science ®Google Scholar
• Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86:533–547. doi:10.1111/bcp.14127
   PubMed Web of Science ®Google Scholar
• Liu X, Huang M, Ye C, Xiao X, Yan C. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: a meta-analysis. Clin Cardiol. 2021;44:472–480. doi:10.1002/clc.23586
   Web of Science ®Google Scholar
• Zhang XL, Zhang XW, Wang TY, et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2021;14(12):e007971. doi:10.1161/CIRCOUTCOMES.121.007971
   PubMed Web of Science ®Google Scholar
• Kido K, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. J Am Pharma Assoc. 2022;62:487–495. doi:10.1016/j.japh.2021.10.027
   Web of Science ®Google Scholar
• Umei M, Kishi M, Sato T, et al. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm. 2017;33:475–482. doi:10.1016/j.joa.2017.05.008Citations:13
   Web of Science ®Google Scholar
• Yamaji H, Murakami T, Hina K, et al. Safety and efficacy of underdosing non-vitamin K antagonist oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation. J Cardiovasc Pharmacol. 2017;69(2):118–126. doi:10.1097/FJC.0000000000000448
   Web of Science ®Google Scholar
• Sato T, Aizawa Y, Fuse K, et al. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. J Stroke Cerebrovasc Dis. 2018;27:3280–3288. doi:10.1016/j.jstrokecerebrovasdis.2018.07.028
   PubMed Web of Science ®Google Scholar
• Cho MS, Yun JE, Park JJ, et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol. 2020;125(9):1332–1338. doi:10.1016/j.amjcard.2020.01.044.Yu
   Web of Science ®Google Scholar
• Kato Y, Hayashi T, Tanahashi N, Takao M. The dose of direct oral anticoagulants and stroke severity in patients with acute ischemic stroke and nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis. 2018;27(6):1490–1496. doi:10.1016/j.jstrokecerebrovasdis.2017.12.038
   Web of Science ®Google Scholar
• Lin YC, Chien SC, Hsieh YC, et al. Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol. 2018;72(5):477–485. doi:10.1016/j.jacc.2018.04.084
   Web of Science ®Google Scholar
• Murata N, Okumura Y, Yokoyama K, et al. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry. Circ J. 2019;83(4):727–735. doi:10.1253/circj.CJ-18-0991
   PubMed Web of Science ®Google Scholar
• Suwa M, Morii I, Kino M, et al. Rivaroxaban or apixaban for non-valvular atrial fibrillation - efficacy and safety of off-label under-dosing: according to plasma concentration. Circ J. 2019;83:991–999. doi:10.1253/circj.CJ-18-1282
   Web of Science ®Google Scholar
• Yu HT, Yang PS, Jang E, et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2020;9(12):e014177. doi:10.1161/JAHA.119.014177
   Web of Science ®Google Scholar
• Yagi N, Suzuki S, Arita T, et al. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non‑valvular atrial fibrillation. Heart Vessels. 2020;35:110–117. doi:10.1007/s00380-019-01457-3
   Web of Science ®Google Scholar
• Chen IC, Chang WT, Hsu PC, et al. Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: a retrospective, observational study. Medicine. 2021;100(23):e26272. doi:10.1097/MD.0000000000026272
   Web of Science ®Google Scholar
• Kadosaka T, Nagai T, Suzuki S, et al. Association of low body weight with clinical outcomes in elderly atrial fibrillation patients receiving apixaban—J-ELD AF registry subanalysis. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-021-07180-4
   Web of Science ®Google Scholar
• Kobayashi T, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Impact of direct oral anticoagulant off-label reduced dose in combination with antiplatelet agents on clinical outcome - propensity score-matching analysis from the DIRECT real-world non-valvular atrial fibrillation registry. Circ Rep. 2020;2(6):289–296. doi:10.1253/circrep.CR-20-0026
   Google Scholar
• Wakamatsu Y, Nagashima K, Watanabe R, et al. Clinical outcomes of off-label underdosing of direct oral anticoagulants after ablation for atrial fibrillation: subanalysis of the AF frontier ablation registry. Int Heart J. 2020;61:1165–1173. doi:10.1536/ihj.20-335
   Web of Science ®Google Scholar
• Steinberg BA, Peter Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose non–vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018;7:e007633. doi:10.1161/JAHA.117.007633
   Web of Science ®Google Scholar
• Briasoulis A, Gao Y, Inampudi C, et al. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. BMC Cardiovasc Disord. 2020;20:42. doi:10.1186/s12872-020-01340-4
   Web of Science ®Google Scholar
• Ashraf H, Agasthi P, Shanbhag A, et al. Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter. Am J Med. 2021;134(6):788–796. doi:10.1016/j.amjmed.2020.12.022
   Web of Science ®Google Scholar
• Sugrue A, Sanborn D, Amin M, et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Am J Card. 2021;144:52–59. doi:10.1016/j.amjcard.2020.12.062
   Web of Science ®Google Scholar
• Salameh M, Gronich N, Stein N, et al. Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real-life study. Clin Pharmacol Ther. 2020;108(6):1265–1273. doi:10.1002/cpt.1952
   Web of Science ®Google Scholar
• Amarenco P, Haas S, Hess S, et al. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother. 2019;5(2):70–79. doi:10.1093/ehjcvp/pvy041
   Web of Science ®Google Scholar
• Camm AJ, Cools F, Virdone S, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–1436. doi:10.1016/j.jacc.2020.07.045
   PubMed Web of Science ®Google Scholar
• Choi J, No JE, Lee JY, et al. Efficacy and safety of clinically driven low-dose treatment with direct oral anticoagulants in Asians with atrial fibrillation: asystematic review and meta-analysis. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-021-07171-5
   Web of Science ®Google Scholar
• Shen NN, Zhang C, Wang N, Wang JL, Gu ZC, Han H. Effectiveness and safety of under or over-dosing of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 148909 patients from 10 real-world studies. Front Pharmacol. 2021;12:645479. doi:10.3389/fphar.2021.645479
   Web of Science ®Google Scholar
• Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450. doi:10.1136/bmjopen-2014-006450
   PubMed Web of Science ®Google Scholar
• Parsons LS. Using SAS® software to perform a case-control match on propensity score in an observational study. Available from: https://support.sas.com/resources/papers/proceedings/proceedings/sugi25/25/po/25p225.pdf. Accessed December 16, 2021.
   Google Scholar
• Ando T, Ooba N, Mochizuki M, et al. Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center. BMC Health Serv Res. 2018;18(1):895. doi:10.1186/s12913-018-3727-0
   Web of Science ®Google Scholar
• Ooba N, Setoguchi S, Ando T. Claims-based definition of death in Japanese claims database: validity and implications. PLoS One. 2013;8:e66116. doi:10.1371/journal.pone.0066116
   Web of Science ®Google Scholar
• Ono Y, Taneda Y, Takeshima T, Iwasaki K, Yasui A. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database. Clin Epidemiol. 2020;12:367–375. doi:10.2147/CLEP.S245555
   Web of Science ®Google Scholar
• Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27(10):476–482. doi:10.1016/j.je.2016.09.009
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228–1234. doi:10.1080/03610910902859574
   Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154. doi:10.1214/aos/1176350951
   Web of Science ®Google Scholar
• Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–609. doi:10.1161/CIRCULATIONAHA.115.017719
   PubMed Web of Science ®Google Scholar
• Walker A, Patrick A, Lauer M, et al. A tool for assessing the feasibility of comparative effectiveness research. Comparat Effective Res. 2013;3:11–20. doi:10.2147/CER.S40357
   Google Scholar
• Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561–570. doi:10.1097/00001648-200009000-00012
   PubMed Web of Science ®Google Scholar
• Li L, Greene T. A weighting analogue to pair matching in propensity score analysis. Int J Biostat. 2013;9(2):215–234. doi:10.1515/ijb-2012-0030
   Google Scholar
• Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113:3390–3400. doi:10.1080/01621459.2016.1260466
   Web of Science ®Google Scholar
• Desai RJ, Rothman KJ, Bateman BT, Hernandez-Diaz S, Huybrechts KH. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017;28(2):249–257. doi:10.1097/EDE.0000000000000595
   PubMed Web of Science ®Google Scholar
• Lin KJ, Jin Y, Gagne J, et al. Longitudinal data discontinuity in electronic health records and consequences for medication effectiveness studies. Clin Pharmacol Ther. 2022;111:243–251. doi:10.1002/cpt.2400
   Web of Science ®Google Scholar
• Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–718. doi:10.1093/aje/kwk052
   PubMed Web of Science ®Google Scholar
• Olsen JB, Torp-Pedersen C, Hansen ML, Lip GYH. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost. 2012;107(6):1172–1179. doi:10.1160/TH12-03-0175
   Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi:10.1378/chest.10-0134
   PubMed Web of Science ®Google Scholar
• Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288–1294. doi:10.1016/j.jclinepi.2004.03.012
   PubMed Web of Science ®Google Scholar
• Webster-Clark M, Huang TY, Hou L, Toh S. Translating claims-based CHA 2 DS 2 -VaSc and HAS-BLED to ICD-10-CM: impacts of mapping strategies. Pharmacoepidemiol Drug Saf. 2020;29(4):409–418. doi:10.1002/pds.4973
   Web of Science ®Google Scholar
• Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33:345–367. doi:10.1016/j.joa.2017.05.004
   PubMed Web of Science ®Google Scholar
• Chong DTT, Andreotti F, Andreotti P, et al. Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian Pacific society of cardiology on strategies for thrombotic and bleeding risk management. Eur Cardiol. 2021;16:e23. doi:10.15420/ecr.2020.43
   PubMed Web of Science ®Google Scholar
• Kim TH, Yang PS, Uhm JS, et al. CHA2DS2-VASc Score (congestive heart failure, hypertension, Age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65–74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study. Stroke. 2017;48(6):1524–1530. doi:10.1161/STROKEAHA.117.016926
   Web of Science ®Google Scholar